natgillin/translations-raw huggingface dataset:
Each 1 ml vial contains 60 micrograms darbepoetin alfa.
Iga 1 ml viaal sisaldab 60 mikrogrammi alfadarbepoetiin.
Each 1 ml vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
Iga 1 ml kontsentraadi viaal sisaldab 0,5 ml veevaba etanooli (395 mg).
Each 1,000 mg vial contains approximately 108 mg sodium.
Iga 1000 mg viaal sisaldab ligikaudu 108 mg naatriumi.
Each 1,000 mg vial contains approximately 108 mg sodium.
Iga viaal sisaldab ligikaudu 108 mg naatriumi.
Each 1.0 g dose contains approximately 6.0 mEq of sodium (approximately 137 mg).
Iga 1,0 g annus sisaldab ligikaudu 6,0 mEq naatriumi (ligikaudu 137 mg).
Each 1.07 ml of solution contains: Fipronil 67 mg, (S)-Methoprene 60.3 mg, Amitraz 80 mg Each 2.14 ml of solution contains: Fipronil 134 mg, (S)-Methoprene 120.6 mg, Amitraz 160 mg Each 4.28 ml of solution contains: Fipronil 268 mg, (S)-Methoprene 241.2 mg, Amitraz 320 mg Each 6.42 ml of solution contains: Fipronil 402 mg, (S)-Methoprene 361.8 mg, Amitraz 480 mg
Iga 1,07 ml lahust sisladab:Fiproniil 67 mg, (S)-Metopreen 60,3 mg, Amitrass 80,0 mg Iga 2,14 ml lahust sisladab Fiproniil 134 mg, (S)-Metopreen 120,6 mg, Amitrass 160,0 mg Iga 4,28 ml lahust sisladab Fiproniil 268 mg, (S)-Metopreen 241,2 mg, Amitrass 320,0 mg Iga 6,42 ml lahust sisladab Fiproniil 402 mg, (S)-Metopreen 361,8 mg, Amitrass 480,0 mg
Each 1.12 ml pipette contains:
Iga 1,12 ml pipett sisaldab:
Each 1.33 ml pipette delivers:
Iga 1,33 ml pipett sisaldab:
Each 1.5 mg film coated tablet contains 36.8 mg lactose.
Üks 1,5 mg õhukese polümeerikattega tablett sisaldab 36,8 mg laktoosi.
Each 1.7 ml of solution contains 78 mg sorbitol (E420).
Iga 1,7 ml lahust sisaldab 78 mg sorbitooli (E420).
Each 10 mg film-coated tablet contains 88 mg lactose.
Üks 10 mg õhukese polümeerikattega tablett sisaldab 88 mg laktoosi.
Each 10 mg Jakavi tablet contains 10 mg of ruxolitinib.
Üks 10 mg Jakavi tablett sisaldab 10 mg ruksolitiniibi.
Each 10 mg pre-filled oral syringe contains 10 mg midazolam (as hydrochloride) in 2 ml solution.
Iga 10 mg suusüstel sisaldab 10 mg midasolaami (vesinikkloriidina) 2 ml lahuses.
Each 10 mg tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.
Iga 10 mg õhukese polümeerikattega tablett sisaldab 10 mg memantiinvesinikkloriidi, mis vastab 8,31 mg memantiinile.
Each 10 mg tablet contains 59 mg lactose (as monohydrate).
Iga 10 mg tablett sisaldab 59 mg laktoosi (monohüdraadina).
Each 10 ml vial contains 200 mg tocilizumab (20 mg/ml).
Iga 10 ml viaal sisaldab 200 mg totsilizumabi (20 mg/ml).
Each 10 ml vial contains approximately 17 mg sodium (less than1 mmol).
Iga 10 ml viaal sisaldab ligikaudu 17 mg naatriumit (vähem kui 1 mmol).
Each 10 ml vial contains approximately 17 mg sodium and each 50 ml vial contains approximately 85 mg sodium.
Iga 10 ml viaal sisaldab ligikaudu 17 mg naatriumit; iga 50 ml viaal sisaldab ligikaudu 85 mg naatriumit.
Each 10 ml vial of Bortezomib Accord must be reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml Bortezomib Accord’i viaali sisu tuleb lahustada 3,5 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 10 ml vial of Bortezomib Hospira must be reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml Bortezomib Hospira viaali sisu tuleb lahustada 3,5 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 10 ml vial of Bortezomib Hospira should be reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml Bortezomib Hospira viaali sisu tuleb lahustada 1,4 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 10 ml vial of Bortezomib SUN must be reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml Bortezomib SUN’i viaali sisu tuleb lahustada 3,5 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 10 ml vial of Bortezomib SUN should be reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml Bortezomib SUN’i viaali sisu tuleb lahustada 1,4 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 10 ml vial of diluent contains: Excipients:
Iga 10 viaal lahustit sisaldab: Abiained:
Each 10 ml vial of VELCADE must be reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml VELCADE viaali sisu tuleb lahustada 3,5 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 10 ml vial of VELCADE should be reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 10 ml VELCADE viaali sisu tuleb lahustada 1,4 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 100 mg film-coated tablet contains 377 mg lactose.
Üks 100 mg õhukese polümeerikattega tablett sisaldab 377 mg laktoosi.
Each 100 mg film-coated tablet of Imatinib Accorcd ontains 100 mg imatinib (as mesilate).
Üks 100 mg õhukese polümeerkattega Imatinib Accord’i tablett sisaldab 100 mg imatiniibi (mesilaadina)
Each 100 mg hard capsule of Imatinib medac contains 100 mg imatinib (as mesilate).
Iga Imatinib medac 100 mg kõvakapsel sisaldab 100 mg imatiniibi (mesülaadina).
Each 100 mg single-use vial containing powder for concentrate for infusion solution designed to deliver 5 ml of 20 mg/ml of trastuzumab emtansine.
Igas 100 mg ühekordselt kasutatavas viaalis sisalduv infusioonilahuse kontsentraadi pulber on mõeldud 5 ml trastuzumabemtansiini lahuse valmistamiseks tugevusega 20 mg/ml.
Each 100 mg vial contains 0.20 mmol (4.6 mg) of sodium.
Üks 100 mg viaal sisaldab 0,20 mmol (4,6 mg) naatriumi.
Each 100 mg vial contains approximately 11 mg sodium.
Iga 100 mg viaal sisaldab ligikaudu 11 mg naatriumi.
Each 100 mg vial contains approximately 11 mg sodium.
Iga viaal sisaldab ligikaudu 11 mg naatriumi.
Each 100 mg vial should be reconstituted with 5.2 mL of single-use sterile water for injections to yield a 20 mg/mL solution.
Iga 100 mg viaali sisu tuleb lahustada 5,2 ml ühekordselt kasutatava steriilse süsteveega, nii et saadakse lahus kontsentratsiooniga 20 mg/ml.
Each 12.5 mg tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin
Üks 12,5 mg tablett sisaldab alogliptiinbensoaati koguses, mis vastab 12,5 mg alogliptiinile.
Each 12.5 mg/1000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1000 mg metformin hydrochloride.
Üks 12,5 mg / 1000 mg õhukese polümeerikattega tablett sisaldab alogliptiinbensoaati koguses, mis vastab 12,5 mg alogliptiinile ja 1000 mg metformiinvesinikkloriidile.
Each 12.5 mg/850 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 850 mg metformin hydrochloride.
Üks 12,5 mg / 850 mg õhukese polümeerikattega tablett sisaldab alogliptiinbensoaati koguses, mis vastab 12,5 mg alogliptiinile ja 850 mg metformiinvesinikkloriidile.
Each 125 mg hard capsule contains 125 mg of aprepitant.
Iga 125 mg kõvakapsel sisaldab 125 mg aprepitanti.
Each 125 microgram pre-filled pen contains 125 micrograms of peginterferon beta-1a in 0.5 mL solution for injection.
Iga 125-mikrogrammine süstel sisaldab 0,5 ml süstelahust, milles on 125 mikrogrammi beeta-1a peginterferooni.
Each 125 microgram pre-filled pen contains 125 micrograms of peginterferon beta-1a* in 0.5 mL solution for injection.
Üks 125-mikrogrammine pen-süstel sisaldab 0,5 ml süstelahuses 125 mikrogrammi beeta-1a* peginterferooni.
Each 125 microgram pre-filled syringe contains 125 micrograms of peginterferon beta-1a* in 0.5 mL solution for injection.
Üks 125-mikrogrammine süstel sisaldab 0,5 ml süstelahuses 125 mikrogrammi beeta-1a* peginterferooni.
Each 15 mg film-coated tablet contains 15 mg rivaroxaban.
Iga 15 mg õhukese polümeerikattega tablett sisaldab 15 mg rivaroksabaani.
Each 15 mg film-coated tablet contains 24.13 mg lactose (as monohydrate), see section 4.4. Each 20 mg film-coated tablet contains 21.76 mg lactose (as monohydrate), see section 4.4.
Iga 15 mg õhukese polümeerikattega tablett sisaldab 24,13 mg laktoosi (monohüdraadina), vt lõik 4.4. Iga 20 mg õhukese polümeerikattega tablett sisaldab 21,76 mg laktoosi (monohüdraadina), vt lõik 4.4.
Each 15 mg Jakavi tablet contains 15 mg of ruxolitinib.
Üks 15 mg Jakavi tablett sisaldab 15 mg ruksolitiniibi.
Each 15 mg orodispersible tablet contains 142.5 mg of lactose (as monohydrate), 0.7875 mg of sucrose and 6.75 mg of aspartame (E951).
Üks 15 mg suus dispergeeruv tablett sisaldab 142,5 mg laktoosi (monohüdraadina), 0,7875 mg sahharoosi ja 6,75 mg aspartaami.
Each 15 mg tablet contains 15 mg of tolvaptan.
Üks 45 mg tablett sisaldab 45 mg tolvaptaani.
Each 15 mg tablet contains 15 mg tolvaptan.
Üks 45 mg tablett sisaldab 45 mg tolvaptaani.
Each 15 mg tablet contains 88 mg lactose (as monohydrate).
Iga 15 mg tablett sisaldab 88 mg laktoosi (monohüdraadina).
Each 15 mg tablet contains approximately 35 mg lactose (as monohydrate).
Üks 15 mg tablett sisaldab ligikaudu 35 mg laktoosi (monohüdraadina).
Each 15 mg tablet contains approximately 35 mg lactose (as monohydrate).
Üks 45 mg tablett sisaldab ligikaudu 12 mg laktoosi (monohüdraadina).
Each 15 ml vial of diluent contains: Excipients:
Iga 15 viaal lahustit sisaldab: Abiained:
Each 150 mg film-coated tablet contains 15.6 mg anhydrous lactose.
Iga 150 mg õhukese polümeerikattega tablett sisaldab 15,6 mg veevaba laktoosi.
Each 160 mg single-use vial containing powder for concentrate for infusion solution designed to deliver 8 ml of 20 mg/ml of trastuzumab emtansine.
Igas 160 mg ühekordselt kasutatavas viaalis sisalduv infusioonilahuse kontsentraadi pulber on mõeldud 8 ml trastuzumabemtansiini lahuse valmistamiseks tugevusega 20 mg/ml.
Each 2 mg film coated tablet contains 36.3 mg lactose.
Üks 2 mg õhukese polümeerikattega tablett sisaldab 36,3 mg laktoosi.
Each 2 mg tablet contains guanfacine hydrochloride equivalent to 2 mg of guanfacine
Üks 2 mg tablett sisaldab guanfatsiinvesinikkloriidi, mis vastab 2 milligrammile guanfatsiinile.
Each 2 ml ampoule contains 10 mg ibuprofen.
Iga 2 ml ampull sisaldab 10 mg ibuprofeeni.
Each 2 ml dose contains:
Iga 2 ml annus sisaldab:
Each 2 ml dose contains:
Iga 2ml annus sisaldab:
Each 2 ml dose of Ibraxion contains the active substance inactivated gene deleted Infectious Bovine Rhinotracheitis (IBR) virus.
Iga 2 ml-ne Ibraxioni annus sisaldab toimeainena deletsiooniga geeniga inaktiveeritud veiste nakkava rinotrahheiidi (infectious bovine rhinotracheitis, IBR) viirust.
Each 2 ml vial contains eribulin mesilate equivalent to 0.88 mg eribulin
Üks 2 ml viaal sisaldab 0,88 mg eribuliinile vastavas koguses eribuliinmesilaati.
Each 2 ml vial contains eribulin mesilate equivalent to 0.88 mg eribulin.
Üks 2 ml viaal sisaldab 0,88 mg eribuliinile vastavas koguses eribuliinmesilaati.
Each 2.5 mg film coated tablet contains 35.8 mg lactose.
Üks 2,5 mg õhukese polümeerikattega tablett sisaldab 35,8 mg laktoosi.
Each 2.5 mg film-coated tablet contains 51.43 mg lactose (see section 4.4).
Iga 2,5 mg õhukese polümeerikattega tablett sisaldab 51,43 mg laktoosi (vt lõik 4.4).
Each 2.5 mg pre-filled oral syringe contains 2.5 mg midazolam (as hydrochloride) in 0.5 ml solution.
Iga 2,5 mg suusüstel sisaldab 2,5 mg midasolaami (vesinikkloriidina) 0,5 ml lahuses.
Each 2.5 ml pipette contains:
Iga 2,5 ml pipett sisaldab:
Each 2.7 ml pre-filled syringe contains 15 mg pegbovigrastim.
Üks 2,7 ml eeltäidetud süstal sisaldab 15 mg pegbovigrastiimi.
Each 2.7 ml pre-filled syringe contains:
Üks 2,7 ml süstal sisaldab:
Each 20 mg film-coated tablet contains 20 mg rivaroxaban.
Iga 20 mg õhukese polümeerikattega tablett sisaldab 20 mg rivaroksabaani.
Each 20 mg Jakavi tablet contains 20 mg of ruxolitinib.
Üks 20 mg Jakavi tablett sisaldab 20 mg ruksolitiniibi.
Each 20 mg tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
Iga 20 mg õhukese polümeerikattega tablett sisaldab 20 mg memantiinvesinikkloriidi, mis vastab 16,62 mg memantiinile.
Each 20 ml syringe contains 6618 mg gadoversetamide equivalent to 10 millimol.
Iga 20 ml süstel sisaldab 6618 mg gadoversetamiidi, mis on ekvivalentne 10 millimooliga.
Each 20 ml vial contains 180 mg of sodium chloride.
Üks 20 ml viaal sisaldab 180 mg naatriumkloriidi.
Each 20 ml vial contains 400 mg tocilizumab (20 mg/ml).
Iga 20 ml viaal sisaldab 400 mg totsilizumabi (20 mg/ml).
Each 20 ml vial contains 500 micrograms ziconotide (as acetate).
Iga 20 ml viaal sisaldab 500 mikrogrammi zikonotiidi (atsetaadina).
Each 20 mL vial of DARZALEX contains 1.6 mmol (37.3 mg) sodium.
Üks 20 ml DARZALEX’i viaal sisaldab 1,6 mmol (37,3 mg) naatriumi.
Each 20 ml vial of lyophilised powder contains:
Iga 20 ml viaal lüofiliseeritud pulbrit sisaldab:
Each 200 mg capsule contains 74.8 mg lactose.
Üks 200 mg kapsel sisaldab 74,8 mg laktoosi.
Each 22 micrograms syringe contains 22 micrograms of interferon beta-1a (6 million IU).
Üks 22 mikrogrammine süstel sisaldab 22 mikrogrammi beeta-1a-interferooni (6 miljonit RÜ).
Each 24 mg/26 mg film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Üks 24 mg/26 mg õhukese polümeerikattega tablett sisaldab 24,3 mg sakubitriili ja 25,7 mg valsartaani naatriumisoola kompleksina.
Each 25 mg film-coated tablet contains 94 mg lactose.
Üks 25 mg õhukese polümeerikattega tablett sisaldab 94 mg laktoosi.
Each 25 mg tablet contains alogliptin benzoate equivalent to 25 mg alogliptin,
Üks 25 mg tablett sisaldab alogliptiinbensoaati koguses, mis vastab 25 mg alogliptiinile.
Each 25 ml vial contains 500 mg vernakalant hydrochloride equivalent to 452.5 mg vernakalant.
Iga 25 ml viaal sisaldab 500 mg vernakalantvesinikkloriidi, mis vastab 452,5 mg vernakalandile.
Each 28 days is called a ‘treatment cycle’.
Iga 28-päevast perioodi nimetatakse ravitsükliks.
Each 28-day pack of Quinsair contains one box of 56 (14 sachets of 4) ampoules and one box holding a Zirela Nebuliser Handset with the Manufacturer’s Instructions for Use.
Üks 28-päevane pakend Quinsair’i sisaldab üht karpi 56 (14 kotikest, igas 4) ampulliga ja üht karpi Zirela käsinebulisaatoriga, millel on kaasas tootja kasutusjuhend.
Each 28-day period is considered one treatment cycle.
28-päevast perioodi loetakse üheks ravitsükliks.
Each 280 cm2 cutaneous patch contains a total of 179 mg of capsaicin or 640 micrograms of capsaicin per cm2 of patch .
Iga 280 cm2 nahaplaaster sisaldab kokku 179 mg kapsaitsiini ehk 640 mikrogrammi kapsaitsiini iga cm2 kohta.
Each 280 cm2 cutaneous patch contains a total of 179 mg of capsaicin or 640 micrograms of capsaicin per cm2 of patch.
Iga 280 cm2 nahaplaaster sisaldab kokku 179 mg kapsaitsiini ehk 640 mikrogrammi kapsaitsiini iga cm2 kohta.
Each 280 cm2 cutaneous patch contains a total of 179 mg of capsaicin or 640 micrograms of capsaicin per cm2 of patch.
Iga 280 cm2 nahaplaaster sisaldab kokku 179 mg kapsaitsiini ehk 640 mikrogrammi kapsaitsiini plaastri iga cm2 kohta.
Each 280 cm2 patch contains a total of 179 mg of capsaicin or 640 micrograms of capsaicin per cm2 of patch (8% w/w).
Iga 280 cm2 nahaplaaster sisaldab kokku 179 mg kapsaitsiini ehk 640 mikrogrammi kapsaitsiini iga cm2 kohta (8 massiprotsenti).
Each 3 mg tablet contains guanfacine hydrochloride equivalent to 3 mg of guanfacine
Üks 3 mg tablett sisaldab guanfatsiinvesinikkloriidi, mis vastab 3 milligrammile guanfatsiinile.
Each 3 ml ampoule contains 60 mg of caffeine citrate (equivalent to 30 mg of caffeine base).
Üks 3 ml ampull sisaldab 60 mg kofeiintsitraati (mis vastab 30 mg kofeiinile).
Each 3 ml pre-filled syringe contains icatibant acetate equivalent to 30 mg icatibant.
Iga 3 ml eeltäidetud süstal sisaldab ikatibantatsetaati, mis on ekvivalentne 30 mg ikatibantiga.
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab-SH antigranulocyte monoclonal antibody fragments) for the preparation of 99mTc labelled LeukoScan.
Iga 3 ml viaal sisaldab 0,31 mg sulesomabi (IMMU-MN3 muriin Fab-SH antigranulotsüütsete monoklonaalsete antikehade fragmente) 99mTc märgistatud LeukoScan valmistamiseks.
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab-SH antigranulocyte monoclonal antibody fragments).
Iga 3 ml viaal sisaldab 0,31 mg sulesomabi (IMMU-MN3 muriin Fab-SH antigranulotsüütsete monoklonaalsete antikehade fragmente).
Each 3 ml vial contains eribulin mesilate equivalent to 1.32 mg eribulin
Üks 3 ml viaal sisaldab 1,32 mg eribuliinile vastavas koguses eribuliinmesilaati.
Each 3.33 ml pipette delivers:
Iga 3,33 ml pipett sisaldab:
Each 30 mg tablet contains 177 mg lactose (as monohydrate).
Iga 30 mg tablett sisaldab 177 mg laktoosi (monohüdraadina).
Each 30 mg tablet contains 2.74 mg of lactose.
Iga 30 mg tablett sisaldab 2,74 mg laktoosi.
Each 30 mg tablet contains 30 mg of tolvaptan.
Üks 60 mg tablett sisaldab 60 mg tolvaptaani.
Each 30 mg tablet contains 30 mg of tolvaptan.
Üks 90 mg tablett sisaldab 90 mg tolvaptaani.
Each 30 mg tablet contains 30 mg tolvaptan.
Üks 60 mg tablett sisaldab 60 mg tolvaptaani.
Each 30 mg tablet contains 30 mg tolvaptan.
Üks 90 mg tablett sisaldab 90 mg tolvaptaani.
Each 30 mg tablet contains approximately 70 mg lactose (as monohydrate).
Üks 30 mg tablett sisaldab ligikaudu 70 mg laktoosi (monohüdraadina).
Each 30 mg tablet contains approximately 70 mg lactose (as monohydrate).
Üks 60 mg tablett sisaldab ligikaudu 16 mg laktoosi (monohüdraadina).
Each 30 mg tablet contains approximately 70 mg lactose (as monohydrate).
Üks 90 mg tablett sisaldab ligikaudu 24 mg laktoosi (monohüdraadina).
Each 300 mg dose is given as two injections of 150 mg.
Iga 300-milligrammine annus manustatakse kahe 150-milligrammise süstena.
Each 4 mg prolonged-release tablet contains 0.525 mg of soya lecithin and 91.125 mg of lactose.
Üks 4 mg toimeainet prolongeeritult vabastav tablett sisaldab 0,525 mg sojaletsitiini ja 91,125 mg laktoosi.
Each 4 mg tablet contains guanfacine hydrochloride equivalent to 4 mg of guanfacine
Üks 4 mg tablett sisaldab guanfatsiinvesinikkloriidi, mis vastab 4 milligrammile guanfatsiinile.
Each 4 mL dose of Imlygic contains approximately 30 mg (1.3 mmol) sodium.
Imlygic’u iga 4 ml annus sisaldab ligikaudu 30 mg (1,3 mmol) naatriumi.
Each 4 mL of solution in the vial contains phenylephrine hydrochloride equivalent to 40.6 mg (10.2 mg/mL) of phenylephrine and ketorolac trometamol equivalent to 11.5 mg (2.88 mg/mL) of ketorolac.
Iga 4 ml lahuse viaal sisaldab fenüülefriinvesinikkloriidi, mis vastab 40,6 mg (10,2 mg/ml) fenüülefriinile, ja ketorolaktrometamooli, mis vastab 11,5 mg (2,88 mg/ml) ketorolakile.
Each 4 ml pipette contains:
Iga 4 ml pipett sisaldab:
Each 4 ml vial contains 80 mg tocilizumab (20 mg/ml).
Iga 4 ml viaal sisaldab 80 mg totsilizumabi (20 mg/ml).
Each 4 ml vial of concentrate contains 2 ml of ethanol anhydrous (1580 mg).
Iga 4 ml kontsentraadi viaal sisaldab 2 ml veevaba etanooli (1580 mg).
Each 4 ml vial of concentrate contains 4 mg topotecan (as hydrochloride).
Üks 4 ml viaal kontsentraati sisaldab 4 mg topotekaani (vesinikkloriidina).
Each 40 mg film-coated tablet contains 40 mg of osimertinib.
Üks 40 mg õhukese polümeerikattega tablett sisaldab 40 mg osimertiniibi.
Each 400 mg capsule contains 149.6 mg of lactose.
Üks 400 mg kapsel sisaldab 149,6 mg laktoosi.
Each 400 mg film-coated tablet of Imatinib Accord contains 400 mg imatinib (as mesilate).
Üks 400 mg õhukese polümeerkattega Imatinib Accord’i tablett sisaldab 400 mg imatiniibi (mesilaadina).
Each 400 mg hard capsule of Imatinib medac contains 400 mg imatinib (as mesilate).
Iga Imatinib medac 400 mg kõvakapsel sisaldab 400 mg imatiniibi (mesülaadina).
Each 400 mg vial should be reconstituted with 20 mL of single-use sterile water for injections to yield a 20 mg/mL solution.
Iga 400 mg viaali sisu tuleb lahustada 20 ml ühekordselt kasutatava steriilse süsteveega, nii et saadakse lahus kontsentratsiooniga 20 mg/ml.
Each 45 mg tablet contains 45 mg of tolvaptan.
Üks 15 mg tablett sisaldab 15 mg tolvaptaani.
Each 45 mg tablet contains 45 mg tolvaptan.
Üks 15 mg tablett sisaldab 15 mg tolvaptaani.
Each 45 mg tablet contains approximately 12 mg lactose (as monohydrate).
Üks 15 mg tablett sisaldab ligikaudu 35 mg laktoosi (monohüdraadina).
Each 49 mg/51 mg film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Üks 49 mg/51 mg õhukese polümeerikattega tablett sisaldab 48,6 mg sakubitriili ja 51,4 mg valsartaani naatriumisoola kompleksina.
Each 5 mg film-coated tablet contains 102.86 mg lactose (see section 4.4).
Iga 5 mg õhukese polümeerikattega tablett sisaldab 102,86 mg laktoosi (vt lõik 4.4).
Each 5 mg Jakavi tablet contains 5 mg of ruxolitinib.
Üks 5 mg Jakavi tablett sisaldab 5 mg ruksolitiniibi.
Each 5 mg orodispersible tablet contains 47.5 mg of lactose (as monohydrate) 0.2625 mg of sucrose and 2.25 mg of aspartame (E951).
Üks 5 mg suus dispergeeruv tablett sisaldab 47,5 mg laktoosi (monohüdraadina), 0,2625 mg sahharoosi ja 2,25 mg aspartaami (E951)
Each 5 mg pre-filled oral syringe contains 5 mg midazolam (as hydrochloride) in 1 ml solution.
Iga 5 mg suusüstel sisaldab 5 mg midasolaami (vesinikkloriidina) 1 ml lahuses.
Each 5 mg tablet contains 63 mg lactose (as monohydrate).
Iga 5 mg tablett sisaldab 63 mg laktoosi (monohüdraadina).
Each 5 mL and 20 mL vial of DARZALEX contains 0.4 mmol and 1.6 mmol (9.3 mg and 37.3 mg) sodium, respectively.
Iga 5 ml või 20 ml DARZALEX’i viaal sisaldab vastavalt 0,4 mmol või 1,6 mmol (9,3 mg või 37,3 mg) naatriumi.
Each 5 ml vial contains 50 mg brivaracetam
Üks 5 ml viaal sisaldab 50 mg brivaratsetaami.
Each 5 ml vial contains 50 mg cytarabine
Üks 5 ml viaal sisaldab 50 mg tsütarabiini
Each 5 ml vial contains 8 mg sodium.
Iga 5 ml viaal sisaldab 8 mg naatriumi.
Each 5 mL vial of DARZALEX contains 0.4 mmol (9.3 mg) sodium.
Üks 5 ml DARZALEX’i viaal sisaldab 0,4 mmol (9,3 mg) naatriumi.
Each 5 ml vial of VELCADE must be reconstituted with 1 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Iga 5 ml VELCADE viaali sisu tuleb lahustada 1 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega.
Each 5.33 ml pipette delivers:
Iga 5,33 ml pipett sisaldab:
Each 50 mg film-coated tablet contains 189 mg lactose.
Üks 50 mg õhukese polümeerikattega tablett sisaldab 189 mg laktoosi.
Each 50 mg vial contains 35.7 mg of sucrose.
Iga 50 mg viaal sisaldab 35,7 mg sahharoosi.
Each 50 ml polypropylene bag contains sodium chloride 0.9% in Water for Injections.
Üks 50 ml polüpropüleenkott sisaldab 0,9% naatriumkloriidi süstevees.
Each 50 mL vial contains 500 mg of olaratumab.
Üks 50 ml viaal sisaldab 500 mg olaratumabi.
Each 50 mL vial contains approximately 146 mg (2.5 mmol) sodium.
Üks 50 ml viaal sisaldab ligikaudu 146 mg (2,5 mmol) naatriumi.
Each 50 mL vial contains approximately 244.4 mg sodium.
Üks 50 ml viaal sisaldab ligikaudu 244,4 mg naatriumi.
Each 50 ml vial contains approximately 85 mg sodium (3.7 mmol).
Iga 50 ml viaal sisaldab ligikaudu 85 mg naatriumit (3,7 mmol).
Each 50 ml vial contains approximately 85 mg sodium.
Üks 50 mg viaal sisaldab ligikaudu 85 mg naatriumit.
Each 500 mg film-coated tablet contains 52 mg anhydrous lactose.
Iga 500 mg õhukese polümeerikattega tablett sisaldab 52 mg veevaba laktoosi.
Each 500 mg vial contains approximately 54 mg sodium.
Iga 500 mg viaal sisaldab ligikaudu 54 mg naatriumi.
Each 500 mg vial contains approximately 54 mg sodium.
Iga viaal sisaldab ligikaudu 54 mg naatriumi.
Each 52 cm2 transdermal patch contains 34.3 mg of granisetron releasing 3.1 mg of granisetron per 24 hours.
Iga 52 cm2 transdermaalne plaaster sisaldab 34,3 mg granisetrooni, millest vabaneb 3,1 mg granisetrooni 24 tunni jooksul.
Each 52 cm2 transdermal patch contains 34.3 mg of granisetron, releasing 3.1 mg of granisetron per 24 hours.
Iga 52 cm2 transdermaalne plaaster sisaldab 34,3 mg granisetrooni, millest vabaneb 3,1 mg granisetrooni 24 tunni jooksul.
Each 56 capsule pack contains one Turbospin powder inhaler device and 7 blisters of 8 capsules or one Turbospin powder inhaler device and 4 blisters of 14 capsules (56 hard capsules) sufficient for 4 weeks use.
Igas 56 kapsliga pakendis on üks pulbriinhalaator Turbospin ja kas 7 blisterit (igas 8 kapslit) või üks pulbriinhalaator Turbospin ja 4 blisterit (igas 14 kapslit, kokku 56 kõvakapslit), millest jätkub kasutusnädalaks.
Each 6 ml vial of concentrate contains 3 ml of ethanol anhydrous (2370 mg).
Iga 6 ml kontsentraadi viaal sisaldab 3 ml veevaba etanooli (2370 mg).